The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology

被引：2

作者：

Tayeb, Haythum O. ^{[1
]}

Khallaf, Roaa A. ^{[2
]}

Muayqil, Taim A. ^{[3
]}

Alkeridy, Walid A. ^{[4
]}

Alibrahim, Fawwaz S. ^{[5
]}

Alfaify, Omar A. ^{[6
]}

Qadi, Najeeb ^{[7
]}

Tarazi, Frank, I ^{[8
,9
]}

机构：

[1] King Abdulaziz Univ, Neurosci Res Unit & Mind & Brain Studies Initiat, Div Neurol,Fac Med, Dept Internal Med, Jeddah, Saudi Arabia

[2] King Saud Univ, Dept Neurol, Neurosci Ctr, Riyadh, Saudi Arabia

[3] King Saud Univ, Neurol Unit, Riyadh, Saudi Arabia

[4] King Saud Univ, Dept Med, Coll Med, Riyadh, Saudi Arabia

[5] King Faisal Specialist Hosp & Res Ctr, Neurol Div, Dept Med,Minist Natl Guard Hlth Affairs, King Abdulaziz Med City, Riyadh, Saudi Arabia

[6] King Faisal Specialist Hosp & Res Ctr, Dept Neurol, Prince Sultan Mil Med City, Riyadh, Saudi Arabia

[7] King Faisal Specialist Hosp & Res Ctr, Neurosci Ctr, Riyadh, Saudi Arabia

[8] Harvard Med Sch, Dept Psychiat & Neurosci, Belmont, MA USA

[9] McLean Hosp, 115 Mill St, Belmont, MA 02178 USA

来源：

NEUROSCIENCES | 2023年 / 28卷 / 02期

关键词：

CARE; DEMENTIA; VERSION;

D O I：

10.17712/nsj.2023.2.20220133

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Alzheimer Disease (AD) constitutes a major global healthcare problem. Standard AD pharmacotherapies offer only modest transient cognitive and behavioral benefits. Aducanumab, an amyloid monoclonal antibody, was the first disease modifying agent to be approved for AD treatment. However, concerns about its efficacy and side effects led regulatory institutions around the world to restrict its use. Lecanemab was the second amyloid antibody to receive accelerated approval for use in early AD. This review and consensus statement was prepared by the Saudi Chapter of Cognitive and Behavioral Neurology to review the current developments in AD immunotherapies from a Saudi perspective. We outline recommendations with regards to offering aducanumab and other future immunotherapies to Saudi AD patients. We describe resources, infrastructure, research, and clinical practice changes that must be attained to transform the patient journey and clinical pathways of AD in Saudi Arabia to enable offering AD immunotherapies in Saudi Arabia.

引用

页码：77 / 84

页数：8

共 50 条

[31] Assessment of knowledge of Alzheimer's disease among medical students at Umm AlQura University, Saudi Arabia
Al-Harbi, Abdulrahman M.
Nmnkany, Abdulkareem M.
Al-Saedi, Ziyad S.
Al-Ahmadi, Ammar A.
Hemdi, Mohannad T.
Tawakul, Abdullah A.
MEDICAL SCIENCE, 2022, 26 (129)
[32] Prevalence and predictors of seizure in patients with Alzheimer's disease at a tertiary care center in Riyadh, Saudi Arabia
Alessa, Mohammed
Alsugheir, Shaden
Almutairi, Nouf
Alqahtani, Abdulaziz
Alhumaid, Lina
Alqahtani, Rahaf
Ahmed, Mohamed Eldigire
TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2021, 20 (11) : 2381 - 2386
[33] Present place and the future of cognitive and behavioral marker in Alzheimer's disease
Robert, P
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S134 - S134
[34] A consensus statement on spinal muscular atrophy management in Saudi Arabia in the context of COVID-19 (vol 25, pg 230, 2020)
Hundallah, Khalid
NEUROSCIENCES, 2020, 25 (05) : 440 - 440
[35] Public knowledge about Alzheimer disease in Mecca Region, Kingdom of Saudi Arabia: a cross-sectional study
Faisal Salem Alhumaidi
Muhammad Irfanullah Siddiqui
Abdulaziz Fahad Altowairqi
Hattan Hassan Alshawkani
Bashar Omar Babkour
Fahad Khalid Alaugla
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 56
[36] Nursing Students' Knowledge and Attitudes Toward Alzheimer's Disease in Saudi Arabia: A Cross-Sectional Study
Alotaibi, Jazi S.
CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)
[37] Public knowledge about Alzheimer disease in Mecca Region, Kingdom of Saudi Arabia: a cross-sectional study
Alhumaidi, Faisal Salem
Siddiqui, Muhammad Irfanullah
Altowairqi, Abdulaziz Fahad
Alshawkani, Hattan Hassan
Babkour, Bashar Omar
Alaugla, Fahad Khalid
EGYPTIAN JOURNAL OF NEUROLOGY PSYCHIATRY AND NEUROSURGERY, 2020, 56 (01):
[38] Managing cognitive impairment in patients with chronic obstructive pulmonary disease (COPD) in Saudi Arabia: what are the current practices?
Siraj, Rayan A.
Alrajeh, Ahmed M.
Alahmari, Mushabbab A.
Alahmadi, Fahad H.
Aldhahir, Abdulelah M.
Alqarni, Abdullah A.
Alqahtani, Jaber S.
Alghamdi, Saeed M.
Alanazi, Turki M.
Alruwaili, Abdullah
Algarni, Saleh S.
Alghamdi, Abdulrhman S.
Alsindi, Tawah H.
Alyami, Mohammed M.
Alshehri, Faisal A.
Alshammari, Talal
Alhasani, Rehab
Alrashed, Khalid
Sabir, Nawaf E.
Mesbah, Ataa F.
ANNALS OF MEDICINE, 2025, 57 (01)
[39] Perception of Mental Health Care Professionals in Saudi Arabia on Computerized Cognitive Behavioral Therapy: Observational Cross-sectional Study
AlHadi, Ahmad N.
Alammari, Khawla A.
Alsiwat, Lojain J.
Alhaidri, Nojood E.
Alabdulkarim, Nouf H.
Altwaijri, Nouf A.
AlSohaili, Shamma A.
JMIR FORMATIVE RESEARCH, 2021, 5 (05)
[40] Review of Social Networking Applications for Infectious Disease Management Systems in Saudi Arabia: Current Status & Future Prospects
Alanezi, Fahad
Alshammary, Miznah
2017 16TH INTERNATIONAL SYMPOSIUM ON DISTRIBUTED COMPUTING AND APPLICATIONS TO BUSINESS, ENGINEERING AND SCIENCE (DCABES), 2017, : 100 - 104

← 1 2 3 4 5 →